ArticleThe oncologist2020

Phase I Study of Alternate-Day Administration of S-1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer.

Toshiki Masuishi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.